SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
EXCLUSIVE: New Report Says Biosimilars Will Earn $55B by 2020, As Pfizer, Actavis, Abbvie Claim U.S. Market
Deals
A Profitable Q1 Leaves Gilead CEO Money to Go Shopping for Possible M&As
May 1, 2015
 · 
5 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Gilead, Achillion Race to Grab Market Share As HCV Populations Abound
April 29, 2015
 · 
5 min read
Biotech Bay
Three Things To Watch With Gilead’s Q1 Earnings
April 28, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Why a Gilead/Vertex Deal Makes More and More Sense
April 28, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Merck & Co. Poised To Enter Oral HCV Market Dominated by Gilead and AbbVie
April 24, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Offers Free Drugs in Georgia in Hep C Eradication Experiment
April 23, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
BioCapital
Buy Vertex Now for $45B Or Risk It All, Analyst Tells Gilead
April 21, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Three Biotechs Well-Positioned for M&A: Gilead, Celgene, and Biogen
April 14, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Drug Development
Will AbbVie’s HCV Candidates Threaten Gilead?
April 9, 2015
 · 
8 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
Gilead Sciences, Inc. To Release Third Quarter 2014 Financial Results On Tuesday, October 28, 2014
October 22, 2014
 · 
1 min read
Policy
Health Canada Issues Notice Of Compliance For Gilead Sciences, Inc.'s Harvoni™ (ledipasvir/sofosbuvir), The First Once-Daily Single Tablet Regimen For The Treatment Of Genotype 1 Chronic Hepatitis C
October 17, 2014
 · 
7 min read
Business
Gilead Sciences, Inc. Release: The Medicines Patent Pool Adds New Sub-Licensing Agreements To Improve Access To Novel Arvs In Developing Countries
September 25, 2014
 · 
5 min read
Policy
Gilead Sciences, Inc. Submits New Drug Application To Japan’s Pharmaceutical And Medical Devices Agency For Fixed-Dose Combination Of Ledipasvir/Sofosbuvir For Chronic Hepatitis C Genotype 1 Infection
September 24, 2014
 · 
1 min read
Biotech Bay
European Commission Grants Marketing Authorization For Gilead Sciences, Inc.’s Zydelig® (Idelalisib) For The Treatment Of Chronic Lymphocytic Leukemia And Follicular Lymphoma
September 19, 2014
 · 
1 min read
Business
Hetero Enters License Agreement With Gilead Sciences, Inc., U.S.A. To Produce Generic Sofosbuvir For Treatment Of Chronic Hepatitis C
September 17, 2014
 · 
1 min read
Business
Mylan Inc. Signs Agreement With Gilead Sciences, Inc. To Accelerate Access To Hepatitis C Treatments, Sovaldi® (Sofosbuvir) And Single Tablet Regimen Of Ledipasvir/Sofosbuvir, in Developing Countries
September 15, 2014
 · 
3 min read
Policy
Gilead Sciences, Inc. Release: First-Line Combination Of Ambrisentan And Tadalafil Reduces Risk Of Clinical Failure Compared To Monotherapy In Pulmonary Arterial Hypertension Outcomes Study
September 8, 2014
 · 
1 min read
Business
Gilead Close To Inking Deal That Would Bring Low-Cost Versions Of $84,000 Solvadi Drug To Poor Countries
September 5, 2014
 · 
1 min read
Biotech Bay
Gilead Sciences, Inc. To Present At Two Upcoming Investor Conferences In September
September 4, 2014
 · 
1 min read
Load More